CMN Weekly (8 November 2024) - Your Weekly CRISPR...
CMN Weekly
Nov. 8, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
YolTech Therapeutics
Company Type: Therapeutic development
Main focus: Developing potentially curative therapies using novel Cas and base editors and LNP delivery systems
Company stage: Clinical
Diseases: Metabolic diseases as well as various genetic disorders and infectious diseases
Genome-editing tool: CRISPR and base editing
Funding stage: Series A
Location: Minhang District, Shanghai, China
Website: YolTech (yoltx.com)
Pipeline: https://www.yoltx.com/pipeline/pipelines
Partners: Wimi Bio
YolTech Therapeutics is a biotechnology company that specialises in gene editing using novel CRISPR-Cas enzymes, base editors, and innovative lipid nanoparticle delivery systems to develop treatments for several diseases, including metabolic disorders and other rare genetic conditions. Their pipeline features ten investigative new therapies, with ongoing clinical trials for transthyretin amyloidosis and familial hypercholesterolemia.
Tags
Related News and Updates
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
